Hidradenitis Suppurativa (HS) is a major public health challenge affecting people globally, which is painful and the hard lumps under the skin are prone to infection. We aimed to investigate whether tofacitinib can help people with HS in a safe and effective way. In this study, we report two cases diagnosed with HS. Tofacitinib was used as a part of the treatment plan. The first patient received 5 mg of tofacitinib twice daily, 36 weeks, and the second one for 24 weeks. Clinical outcomes are described. The efficacy of tofacitinib in HS was confirmed in our study. The clinical characteristics of the patients improved after receiving tofacitinib. Lesions discharge significantly reduced, particularly in the axillary area. Tofacitinib may be useful as an adjuvant therapy when used in combination with other treatments. Further research in this area is required to improve our understanding of treatment with tofacitinib at HS.